Targeted next generation sequencing identifies markers of response to PD-1 blockade

Cancer Immunology Research

Volumn 4, Issue 11, 2016, Pages 959-967

  Johnson, Douglas B ^a   Frampton, Garrett M ^c   Rioth, Matthew J ^a   Yusko, Erik ^d   Xu, Yaomin ^a   Guo, Xingyi ^a   Ennis, Riley C ^c   Fabrizio, David ^c   Chalmers, Zachary R ^c   Greenbowe, Joel ^c   Ali, Siraj M ^c   Balasubramanian, Sohail ^c   Sun, James X ^c   He, Yuting ^c   Frederick, Dennie T ^e   Puzanov, Igor ^a   Balko, Justin M ^a,b   Cates, Justin M ^a   Ross, Jeffrey S ^c   Sanders, Catherine ^d   Robins, Harlan ^d   Shyr, Yu ^a   Miller, Vincent A ^c   Stephens, Philip J ^c   Sullivan, Ryan J ^e   Sosman, Jeffrey A ^a   Lovly, Christine M ^a,b   more..

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FOUNDATION MEDICINE   (United States)

^d ADAPTIVE BIOTECHNOLOGIES   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; B RAF KINASE; NIVOLUMAB; PEMBROLIZUMAB; T LYMPHOCYTE RECEPTOR; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTOME; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLONAL VARIATION; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; LRP1B GENE; MALE; MELANOMA; MUTATIONAL LOAD; NEXT GENERATION SEQUENCING; NF1 GENE; ONCOGENE N RAS; OVERALL SURVIVAL; POST TREATMENT SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VERY ELDERLY; WHOLE EXOME SEQUENCING; ANTAGONISTS AND INHIBITORS; CANCER STAGING; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MUTATION; NEOPLASM; PROGNOSIS; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; TRANSCRIPTOME;

EID: 85016150420     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-16-0143     Document Type: Article

References (27)

1. Wolchok JD. PD-1 blockers. Cell 2015;162:937.
2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermottDF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
3. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advancedmelanoma. N Engl J Med 2015;372:2521-32.
4. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7.
5. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
6. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
7. Snyder A, Makarov V,Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic Basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
8. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015;350:207-11.
9. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P,Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in nonsmall cell lung cancer. Science 2015;348:124-8.
10. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016;351: 1463-9.
11. Le DT, Uram JN,WangH, Bartlett BR, KemberlingH, Eyring AD, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-20.
12. Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, et al. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res 2015;3: 288-95.
13. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 2015;6:202-16.
14. Spranger S, Bao R,Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 2015;523:231-5.
15. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al.MYC regulates the antitumor immune response through CD47 and PD-L1. Science 2016; 352:227-31.
16. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31: 1023-31.
17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
18. GerlingerM, Quezada SA, Peggs KS, Furness AJ, Fisher R, Marafioti T, et al. Ultra-deep T-cell receptor sequencing reveals the complexity and intratumour heterogeneity of T-cell clones in renal cell carcinomas. J Pathol 2013;231:424-32.
19. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 2015;161:1681-96.
20. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012;44:1006-14.
21. Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, et al. Ipilimumab for patients with advanced mucosal melanoma. Oncologist 2013;18:726-32.
22. Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of theDana-Farber Cancer Institute,Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne Experience. Cancer 2013;119:3687-95.
23. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 2016;165:35-44.
24. Smith DI, Zhu Y, McAvoy S, Kuhn R. Common fragile sites, extremely large genes, neural development and cancer. Cancer Lett 2006;232:48-57.
25. Gubin MM, Schreiber RD. CANCER. The odds of immunotherapy success. Science 2015;350:158-9.
26. Hansen AR, Siu LL. PD-L1 testing in cancer: challenges in companion diagnostic development. JAMA Oncol 2015:1-2.
27. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909-20.